agxАндрология и генитальная хирургияAndrology and Genital Surgery2070-97812412-890210.17650/2070-9781-2023-24-3-33-41agx-692Research ArticleОБЗОРНАЯ СТАТЬЯREVIEWАндрологические аспекты нарушений секреции пролактинаAndrological aspects of prolactin secretion disordershttps://orcid.org/0000-0001-6316-9020ТюзиковИ. А.TyuzikovI. A.

Тюзиков Игорь Адамович.

150000 Ярославль, Первомайский переулок, 3в

Igor A. Tyuzikov.

3v Pervomaiskiy Ln., Yaroslavl 150000

phoenix-67@list.ruГрековЕ. А.GrekovE. A.

123022 Москва, ул. 1905 года, 23

23 1905 Goda St., Moscow 123022

СмирновА. В.SmirnovA. V.

197110 Санкт-Петербург, пр-кт Динамо, 3

3 Dynamo Ave., St. Petersburg 197110

Медицинский центр «Тандем-Плюс»РоссияMedical Center “Tandem-Plus”Russian FederationКлиника “Hormone Life”Россия“Hormone Life” ClinicRussian FederationСПб ГБУЗ «Городская клиническая больница № 31»РоссияSaint Petersburg City Clinical Hospital No. 31Russian Federation2023120920232433341Copyright © Тюзиков И.А., Греков Е.А., Смирнов А.В., 20232023Тюзиков И.А., Греков Е.А., Смирнов А.В.Tyuzikov I.A., Grekov E.A., Smirnov A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://agx.elpub.ru/jour/article/view/692

С момента открытия пролактина научно-практический интерес к нему в основном был связан с женской эндокринологией и репродуктологией. При этом физиология и патофизиология пролактина у мужчин ввиду исторически сложившейся трактовки функций данного гормона только лишь как эндокринного регулятора женской репродуктивной системы долгое время оставались недостаточно изученными. Однако в течение последних десятилетий стали накапливаться убедительные научные данные о том, что пролактин столь же важен для мужчин, как и для женщин. Показано, что у обоих полов пролактин обладает не только важными классическими (репродуктивными) эффектами, но и выполняет широкий спектр нерепродуктивных физиологических функций во многих органах и клетках. В частности, к настоящему времени описаны как репродуктивные, так и различные гормонально-метаболические, психосоматические, иммунно-воспалительные, сексуальные расстройства, обусловленные нарушениями секреции пролактина (гипо- и гиперпролактинемия).

В обзорной статье на основе доступной современной литературы рассматриваются общие вопросы эндокринологии и физиологии пролактина у мужчин, а также основные андрологические проявления нарушений его секреции со стороны мужской репродуктивной системы, мужской сексуальной функции и предстательной железы.

Since the discovery of prolactin, scientific and practical interest in it has been focused exclusively from the standpoint of female endocrinology and reproductology. At the same time, the physiology and pathophysiology of prolactin in men, due to the historically established interpretation of the functions of this hormone only as an endocrine regulator    of the female reproductive system, have remained insufficiently studied for a long time. However, in recent decades, convincing scientific evidence has begun to accumulate that prolactin is just as important for men as for women. It has been shown that in both sexes prolactin not only exhibits important classical (reproductive) effects, but has a wide range of non-productive physiological functions in many organs and cells. In particular, to date, not only reproductive,   but various hormonal-metabolic, psychosomatic, immune-inflammatory, sexual disorders caused by disorders of prolactin secretion (hypo- and hyperprolactinemia) have been described.

The review article, based on the available modern literature, examines the general issues of endocrinology and physiology of prolactin in men, as well as the main andrological manifestations of disorders of its secretion by male reproduction, male sexual function and prostate gland.

пролактингипопролактинемиягиперпролактинемиястероидогенезсперматогенезмужская фертильностьмужская сексуальная функцияпредстательная железаprolactinhypoprolactinemiahyperprolactinemiasteroidogenesisspermatogenesismale fertilitymale sexual functionprostate glandReferencesPhillipps H.R., Yip S.H., Grattan D.R. Patterns of prolactin secretion. Mol Cell Endocrinol 2020;502:10679. DOI: 10.1016/j.mce.2019.110679Phillipps H.R., Yip S.H., Grattan D.R. Patterns of prolactin secretion. Mol Cell Endocrinol 2020;502:10679. DOI: 10.1016/j.mce.2019.110679Rohn R.D. Galactorrhea in the adolescent. J Adolesc Health Care 1984;5(1):37–49. DOI: 10.1016/s0197-0070(84)80244-2Rohn R.D. Galactorrhea in the adolescent. J Adolesc Health Care 1984;5(1):37–49. DOI: 10.1016/s0197-0070(84)80244-2Cabrera-Reyes E.A., Limón-Morales O., Rivero-Segura N.A. et al. Prolactin function and putative expression in the brain. Endocrinology 2017;57(2):199–213. DOI: 10.1007/s12020-017-1346-xCabrera-Reyes E.A., Limón-Morales O., Rivero-Segura N.A. et al. Prolactin function and putative expression in the brain. Endocrinology 2017;57(2):199–213. DOI: 10.1007/s12020-017-1346-xParagliola R.M., Binart N., Salvatori R. Prolactin. In: The Pituitary. Ed. by S. Melmed. 5th edn. Academic Press, 2022. P. 131–172. DOI: 10.1016/B978-0-323-99899-4.00025-1Paragliola R.M., Binart N., Salvatori R. Prolactin. In: The Pituitary. Ed. by S. Melmed. 5th edn. Academic Press, 2022. P. 131–172. DOI: 10.1016/B978-0-323-99899-4.00025-1Macotela Y., Ruiz-Herrera X., Vázquez-Carrillo D.I. et al. The beneficial metabolic actions of prolactin. Front Endocrinol (Lausanne) 2022;13:1001703. DOI: 10.3389/fendo.2022.1001703Macotela Y., Ruiz-Herrera X., Vázquez-Carrillo D.I. et al. The beneficial metabolic actions of prolactin. Front Endocrinol (Lausanne) 2022;13:1001703. DOI: 10.3389/fendo.2022.1001703Lopez-Vicchi F., De Winne C., Brie B. et al. Metabolic functions of prolactin: Physiological and pathological aspects. Neuroendocrinol 2020;32(11):e12888. DOI: 10.1111/jne.12888Lopez-Vicchi F., De Winne C., Brie B. et al. Metabolic functions of prolactin: Physiological and pathological aspects. Neuroendocrinol 2020;32(11):e12888. DOI: 10.1111/jne.12888Адамян Л.В., Ярмолинская М.И., Суслова Е.В. Синдром гиперпролактинемии: от теории к практике. Проблемы репродукции 2020;26(2):27–33. DOI: 10.17116/repro20202602127Adamyan L.V., Yarmolinskaya M.I., Suslova E.V. Hyperprolactinemia syndrome: from theory to practice. Problemy reprodukcii = Reproduction Problems 2020;26(2):27–33. (In Russ.). DOI: 10.17116/repro20202602127Bernard V., Young J., Binart N. Prolactin – a pleiotropic factor in health and disease. Nat Rev Endocrinol 2019;15(6):356–65. DOI: 10.1038/s41574-019-0194-6Bernard V., Young J., Binart N. Prolactin – a pleiotropic factor in health and disease. Nat Rev Endocrinol 2019;15(6):356–65. DOI: 10.1038/s41574-019-0194-6Pirchio R., Graziadio C., Colao A. et al. Metabolic effects of prolactin. Front Endocrinol (Lausanne) 2022;13:1015520. DOI: 10.3389/fendo.2022.1015520Pirchio R., Graziadio C., Colao A. et al. Metabolic effects of prolactin. Front Endocrinol (Lausanne) 2022;13:1015520. DOI: 10.3389/fendo.2022.1015520Rastrelli G., Corona G., Maggi M. The role of prolactin in andrology: what is new? Rev Endocr Metab Disord 2015;16(3):233–48. DOI: 10.1007/s11154-015-9322-3Rastrelli G., Corona G., Maggi M. The role of prolactin in andrology: what is new? Rev Endocr Metab Disord 2015;16(3):233–48. DOI: 10.1007/s11154-015-9322-3Al-Karagholi M.A., Kalatharan V., Ghanizada H. et al. Prolactin in headache and migraine: a systematic review of clinical studies. Cephalalgia 2023;43(2):3331024221136286. DOI: 10.1177/03331024221136286Al-Karagholi M.A., Kalatharan V., Ghanizada H. et al. Prolactin in headache and migraine: a systematic review of clinical studies. Cephalalgia 2023;43(2):3331024221136286. DOI: 10.1177/03331024221136286Grattan D.R. Coordination or coincidence? The relationship between prolactin and gonadotropin secretion. Trends Endocrinol Metab 2018;29(1):3–5. DOI: 10.1016/j.tem.2017.11.004Grattan D.R. Coordination or coincidence? The relationship between prolactin and gonadotropin secretion. Trends Endocrinol Metab 2018;29(1):3–5. DOI: 10.1016/j.tem.2017.11.004Clarkson J., Han S.Y., Piet R. et al. Definition of the hypothalamic GnRH pulse generator in mice. Proc Natl Acad Sci U S A 2017; 114(47):E10216–23. DOI: 10.1073/pnas.1713897114Clarkson J., Han S.Y., Piet R. et al. Definition of the hypothalamic GnRH pulse generator in mice. Proc Natl Acad Sci U S A 2017; 114(47):E10216–23. DOI: 10.1073/pnas.1713897114Dabbous Z., Atkin S.L. Hyperprolactinaemia in male infertility: clinical case scenarios. Arab J Urol 2017;16(1):44–52. DOI: 10.1016/j.aju.2017.10.002Dabbous Z., Atkin S.L. Hyperprolactinaemia in male infertility: clinical case scenarios. Arab J Urol 2017;16(1):44–52. DOI: 10.1016/j.aju.2017.10.002Gonzales G.F., Velasquez G., Garcia-Hjarles M. Hypoprolactinemia as related to seminal quality and serum testosterone. Arch Androl 1989;23(3):259–65. DOI: 10.3109/01485018908986849Gonzales G.F., Velasquez G., Garcia-Hjarles M. Hypoprolactinemia as related to seminal quality and serum testosterone. Arch Androl 1989;23(3):259–65. DOI: 10.3109/01485018908986849Firdolas F., Ogras M.S., Ozan T. et al. In vitro examination of effects of hyperprolactinemia and hypoprolactinemia on seminal vesicle contractions. Urol 2013;81(3):557–61. DOI: 10.1016/j.urology.2012.11.025Firdolas F., Ogras M.S., Ozan T. et al. In vitro examination of effects of hyperprolactinemia and hypoprolactinemia on seminal vesicle contractions. Urol 2013;81(3):557–61. DOI: 10.1016/j.urology.2012.11.025Sengupta P., Dutta S., Karkada I.R., Chinni S.V. Endocrinopathies and male infertility. Life (Basel) 2021;12(1):10. DOI: 10.3390/life12010010Sengupta P., Dutta S., Karkada I.R., Chinni S.V. Endocrinopathies and male infertility. Life (Basel) 2021;12(1):10. DOI: 10.3390/life12010010Vander B.M., Wyns C. Fertility and infertility: definition and epidemiology. Clin Biochem 2018;62:2–10. DOI: 10.1016/j.clinbiochem.2018.03.012Vander B.M., Wyns C. Fertility and infertility: definition and epidemiology. Clin Biochem 2018;62:2–10. DOI: 10.1016/j.clinbiochem.2018.03.012Ambulkar S.S., Darves-Bornoz A.L., Fantus R.J. et al. Prevalence of hyperprolactinemia and clinically apparent prolactinomas in men undergoing fertility evaluation. Urology 2022;159:114–9. DOI: 10.1016/j.urology.2021.03.007Ambulkar S.S., Darves-Bornoz A.L., Fantus R.J. et al. Prevalence of hyperprolactinemia and clinically apparent prolactinomas in men undergoing fertility evaluation. Urology 2022;159:114–9. DOI: 10.1016/j.urology.2021.03.007Samperi I., Lithgow K., Karavitaki N. Hyperprolactinaemia. J Clin Med 2019;8(12):2203. DOI: 10.3390/jcm8122203Samperi I., Lithgow K., Karavitaki N. Hyperprolactinaemia. J Clin Med 2019;8(12):2203. DOI: 10.3390/jcm8122203Corona G., Isidori A.M., Aversa A. et al. Endocrinologic control of men’s sexual desire and arousal/erection. J Sex Med 2016;13(3):317–37. DOI: 10.1016/j.jsxm.2016.01.007Corona G., Isidori A.M., Aversa A. et al. Endocrinologic control of men’s sexual desire and arousal/erection. J Sex Med 2016;13(3):317–37. DOI: 10.1016/j.jsxm.2016.01.007Krysiak R., Okopień B. Sexual functioning in hyperprolactinemic patients treated with cabergoline or bromocriptine. Am J Ther 2019;26(4):e433–40. DOI: 10.1097/MJT.0000000000000777Krysiak R., Okopień B. Sexual functioning in hyperprolactinemic patients treated with cabergoline or bromocriptine. Am J Ther 2019;26(4):e433–40. DOI: 10.1097/MJT.0000000000000777Fiala L., Lenz J., Sajdlova R. Effect of increased prolactin and psychosocial stress on erectile function. Andrologia 2021;53(4):e14009. DOI: 10.1111/and.14009.Fiala L., Lenz J., Sajdlova R. Effect of increased prolactin and psychosocial stress on erectile function. Andrologia 2021;53(4):e14009. DOI: 10.1111/and.14009.Xu Z.H., Pan D., Liu T.Y. et al. Effect of prolactin on penile erection: a cross-sectional study. Asian J Androl 2019;21(6):587–91. DOI: 10.4103/aja.aja_22_19Xu Z.H., Pan D., Liu T.Y. et al. Effect of prolactin on penile erection: a cross-sectional study. Asian J Androl 2019;21(6):587–91. DOI: 10.4103/aja.aja_22_19Corona G., Mannucci E., Jannini E.A. et al. Hypoprolactinemia: a new clinical syndrome in patients with sexual dysfunction. J Sex Med 2009;6(5):1457–66. DOI: 10.1111/j.1743-6109.2008.01206.xCorona G., Mannucci E., Jannini E.A. et al. Hypoprolactinemia: a new clinical syndrome in patients with sexual dysfunction. J Sex Med 2009;6(5):1457–66. DOI: 10.1111/j.1743-6109.2008.01206.xCorona G., Rastrelli G., Comeglio P. et al. The metabolic role of prolactin: systematic review, meta-analysis and preclinical considerations. Expert Rev Endocrinol Metab 2022;17(6):533–45. DOI: 10.1080/17446651.2022.2144829Corona G., Rastrelli G., Comeglio P. et al. The metabolic role of prolactin: systematic review, meta-analysis and preclinical considerations. Expert Rev Endocrinol Metab 2022;17(6):533–45. DOI: 10.1080/17446651.2022.2144829Krysiak R., Kowalcze K., Okopień B. Sexual function and depressive symptoms in men with hypoprolactinaemia secondary to overtreatment of prolactin excess: a pilot study. Endocrinol Diabetes Nutr (Engl Ed) 2022:69(4):279–88. DOI: 10.1016/j.endien.2021.03.004Krysiak R., Kowalcze K., Okopień B. Sexual function and depressive symptoms in men with hypoprolactinaemia secondary to overtreatment of prolactin excess: a pilot study. Endocrinol Diabetes Nutr (Engl Ed) 2022:69(4):279–88. DOI: 10.1016/j.endien.2021.03.004Maurya M.R, Munshi R., Zambare S. Melanocortin receptors: emerging targets for the treatment of pigmentation, inflammation, stress, weight disorders and sexual dysfunction. Curr Drug Targets 2023;24(2):151–6. DOI: 10.2174/1389450124666221108143006Maurya M.R, Munshi R., Zambare S. Melanocortin receptors: emerging targets for the treatment of pigmentation, inflammation, stress, weight disorders and sexual dysfunction. Curr Drug Targets 2023;24(2):151–6. DOI: 10.2174/1389450124666221108143006Rahmani B., Ghasemi R., Dargahi L. et al. Neurosteroids; potential underpinning roles in maintaining homeostasis. Gen Comp Endocrinol 2016;225:242–50. DOI: 10.1016/j.ygcen.2015.09.030Rahmani B., Ghasemi R., Dargahi L. et al. Neurosteroids; potential underpinning roles in maintaining homeostasis. Gen Comp Endocrinol 2016;225:242–50. DOI: 10.1016/j.ygcen.2015.09.030Goffin V. Prolactin receptor targeting in breast and prostate cancers: new insights into an old challenge. Pharmacol Ther 2017;179:111–26. DOI: 10.1016/j.pharmthera.2017.05.009Goffin V. Prolactin receptor targeting in breast and prostate cancers: new insights into an old challenge. Pharmacol Ther 2017;179:111–26. DOI: 10.1016/j.pharmthera.2017.05.009Karayazi Atıcı Ö., Govindrajan N., Lopetegui-González I., Shemanko C.S. Prolactin: a hormone with diverse functions from mammary gland development to cancer metastasis. Semin Cell Dev Biol 2021;114:159–70. DOI: 10.1016/j.semcdb.2020.10.005Karayazi Atıcı Ö., Govindrajan N., Lopetegui-González I., Shemanko C.S. Prolactin: a hormone with diverse functions from mammary gland development to cancer metastasis. Semin Cell Dev Biol 2021;114:159–70. DOI: 10.1016/j.semcdb.2020.10.005Costello L.C., Franklin R.B. Testosterone and prolactin regulation of metabolic genes and citrate metabolism of prostate epithelial cells. Horm Metab Res 2002;34(8):417–24. DOI: 10.1055/s-2002-33598Costello L.C., Franklin R.B. Testosterone and prolactin regulation of metabolic genes and citrate metabolism of prostate epithelial cells. Horm Metab Res 2002;34(8):417–24. DOI: 10.1055/s-2002-33598Camargo A.C.L., Constantino F.B., Santos S.A.A. et al. Influence of postnatal prolactin modulation on the development and maturation of ventral prostate in young rats. Reprod Fertil Dev 2018;30(7): 969–79. DOI: 10.1071/RD17343Camargo A.C.L., Constantino F.B., Santos S.A.A. et al. Influence of postnatal prolactin modulation on the development and maturation of ventral prostate in young rats. Reprod Fertil Dev 2018;30(7): 969–79. DOI: 10.1071/RD17343López Fontana G., Rey L., Santiano F. et al. Changes in prolactin receptor location in prostate tumors. Arch Esp Urol 2021;74(4):419–26. PMID: 33942735.López Fontana G., Rey L., Santiano F. et al. Changes in prolactin receptor location in prostate tumors. Arch Esp Urol 2021;74(4):419–26. PMID: 33942735.La Vignera S., Condorelli R.A., Russo G.I. et al. Endocrine control of benign prostatic hyperplasia. Andrology 2016;4(3):404–11. DOI: 10.1111/andr.12186La Vignera S., Condorelli R.A., Russo G.I. et al. Endocrine control of benign prostatic hyperplasia. Andrology 2016;4(3):404–11. DOI: 10.1111/andr.12186Loutchanwoot P., Srivilai P., Jarry H. Effects of the natural endocrine disruptor equol on the pituitary function in adult male rats. Toxicol 2013;304:69–75. DOI: 10.1016/j.tox.2012.11.017Loutchanwoot P., Srivilai P., Jarry H. Effects of the natural endocrine disruptor equol on the pituitary function in adult male rats. Toxicol 2013;304:69–75. DOI: 10.1016/j.tox.2012.11.017Govindaraj V., Arya S.V., Rao A.J. Differential action of glycoprotein hormones: significance in cancer progression. Horm Cancer 2014;5(1):1–10. DOI: 10.1007/s12672-013-0164-8Govindaraj V., Arya S.V., Rao A.J. Differential action of glycoprotein hormones: significance in cancer progression. Horm Cancer 2014;5(1):1–10. DOI: 10.1007/s12672-013-0164-8Slaunwhite W.R. Jr., Sharma M. Effects of hypophysectomy and prolactin replacement therapy on prostatic response to androgen in orchiectomized rats. Biol Reprod 1977;17(4):489–92. DOI: 10.1095/biolreprod17.4.489Slaunwhite W.R. Jr., Sharma M. Effects of hypophysectomy and prolactin replacement therapy on prostatic response to androgen in orchiectomized rats. Biol Reprod 1977;17(4):489–92. DOI: 10.1095/biolreprod17.4.489Rui H., Purvis K. Independent control of citrate production and ornithine decarboxylase by prolactin in the lateral lobe of the rat prostate. Mol Cell Endocrinol 1987;52(1–2):91–5. DOI: 10.1016/0303-7207(87)90101-8Rui H., Purvis K. Independent control of citrate production and ornithine decarboxylase by prolactin in the lateral lobe of the rat prostate. Mol Cell Endocrinol 1987;52(1–2):91–5. DOI: 10.1016/0303-7207(87)90101-8Zanatelli M., Colleta S.J., Guerra L.H.A. et al. Prolactin promotes a partial recovery from the atrophy of both male and female gerbil prostates caused by castration. Reprod Biol Endocrinol 2021;19(1):94. DOI: 10.1186/s12958-021-00777-2Zanatelli M., Colleta S.J., Guerra L.H.A. et al. Prolactin promotes a partial recovery from the atrophy of both male and female gerbil prostates caused by castration. Reprod Biol Endocrinol 2021;19(1):94. DOI: 10.1186/s12958-021-00777-2Constantino F.B., Camargo A.C.L., Santos S.A.A. et al. The prostate response to prolactin modulation in adult castrated rats subjected to testosterone replacement. J Mol Histol 2017;48(5–6): 403–15. DOI: 10.1007/s10735-017-9738-zConstantino F.B., Camargo A.C.L., Santos S.A.A. et al. The prostate response to prolactin modulation in adult castrated rats subjected to testosterone replacement. J Mol Histol 2017;48(5–6): 403–15. DOI: 10.1007/s10735-017-9738-zCostello L.C., Franklin R.B. Testosterone, prolactin, and oncogenic regulation of the prostate gland. A new concept: testosterone-independent malignancy is the development of prolactin-dependent malignancy. Oncol Rev 2018;12(2):356. DOI: 10.4081/oncol.2018.356Costello L.C., Franklin R.B. Testosterone, prolactin, and oncogenic regulation of the prostate gland. A new concept: testosterone-independent malignancy is the development of prolactin-dependent malignancy. Oncol Rev 2018;12(2):356. DOI: 10.4081/oncol.2018.356Di Zazzo E., Galasso G., Giovannelli P. et al. Estrogens and their receptors in prostate cancer: therapeutic implications. Front Oncol 2018;8:2. DOI: 10.3389/fonc.2018.00002Di Zazzo E., Galasso G., Giovannelli P. et al. Estrogens and their receptors in prostate cancer: therapeutic implications. Front Oncol 2018;8:2. DOI: 10.3389/fonc.2018.00002Dobbs R.W., Malhotra N.R., Greenwald D.T. et al. Estrogens and prostate cancer. Prostate Cancer Prostatic Dis 2019;22(2):185–94. DOI: 10.1038/s41391-018-0081-6Dobbs R.W., Malhotra N.R., Greenwald D.T. et al. Estrogens and prostate cancer. Prostate Cancer Prostatic Dis 2019;22(2):185–94. DOI: 10.1038/s41391-018-0081-6Van Coppenolle F., Slomianny C., Carpentier F. et al. Effects of hyperprolactinemia on rat prostate growth: evidence of androgeno-dependence. Am J Physiol Endocrinol Metab 2001;280(1):E120–9. DOI: 10.1152/ajpendo.2001.280.1.E120Van Coppenolle F., Slomianny C., Carpentier F. et al. Effects of hyperprolactinemia on rat prostate growth: evidence of androgeno-dependence. Am J Physiol Endocrinol Metab 2001;280(1):E120–9. DOI: 10.1152/ajpendo.2001.280.1.E120Zhang Y., Gc S., Patel S.B. et al. Growth hormone (GH) receptor (GHR)-specific inhibition of GH-Induced signaling by soluble IGF-1 receptor (sol IGF-1R). Mol Cell Endocrinol 2019;492:110445. DOI: 10.1016/j.mce.2019.05.004Zhang Y., Gc S., Patel S.B. et al. Growth hormone (GH) receptor (GHR)-specific inhibition of GH-Induced signaling by soluble IGF-1 receptor (sol IGF-1R). Mol Cell Endocrinol 2019;492:110445. DOI: 10.1016/j.mce.2019.05.004Kavarthapu R., Anbazhagan R., Dufau M.L. Crosstalk between PRLR and EGFR/HER2 signaling pathways in breast cancer. Cancers (Basel) 2021;13(18):4685. DOI: 10.3390/cancers13184685Kavarthapu R., Anbazhagan R., Dufau M.L. Crosstalk between PRLR and EGFR/HER2 signaling pathways in breast cancer. Cancers (Basel) 2021;13(18):4685. DOI: 10.3390/cancers13184685Borcherding D.C., Hugo E.R., Fox S.R. et al. Suppression of breast cancer by small molecules that block the prolactin receptor. Cancers (Basel) 2021;13(11):2662. DOI: 10.3390/cancers13112662Borcherding D.C., Hugo E.R., Fox S.R. et al. Suppression of breast cancer by small molecules that block the prolactin receptor. Cancers (Basel) 2021;13(11):2662. DOI: 10.3390/cancers13112662Sackmann-Sala L., Goffin V. Prolactin-induced prostate tumorigenesis. Adv Exp Med Biol 2015;846:221–42. DOI: 10.1007/978-3-319-12114-7_10Sackmann-Sala L., Goffin V. Prolactin-induced prostate tumorigenesis. Adv Exp Med Biol 2015;846:221–42. DOI: 10.1007/978-3-319-12114-7_10Minami H., Ando Y., Tamura K. et al. Phase I study of LFA102 in patients with advanced breast cancer or castration-resistant prostate cancer. Anticancer Res 2020;40(9):5229–35. DOI: 10.21873/anticanres.14526Minami H., Ando Y., Tamura K. et al. Phase I study of LFA102 in patients with advanced breast cancer or castration-resistant prostate cancer. Anticancer Res 2020;40(9):5229–35. DOI: 10.21873/anticanres.14526Agarwal N., Machiels J.P., Suárez C. et al. Phase I study of the prolactin receptor antagonist LFA102 in metastatic breast and castration-resistant prostate cancer. Oncologist 2016;21(5):535–6. DOI: 10.1634/theoncologist.2015-0502Agarwal N., Machiels J.P., Suárez C. et al. Phase I study of the prolactin receptor antagonist LFA102 in metastatic breast and castration-resistant prostate cancer. Oncologist 2016;21(5):535–6. DOI: 10.1634/theoncologist.2015-0502Carrasco-Ceballos J.M., Barrera-Hernández D., Locia-Espinosa J. et al. Involvement of the PRL-PAK1 pathway in cancer cell migration. Cancer Diagn Progn 2023;3(1):17–25. DOI: 10.21873/cdp.10174Carrasco-Ceballos J.M., Barrera-Hernández D., Locia-Espinosa J. et al. Involvement of the PRL-PAK1 pathway in cancer cell migration. Cancer Diagn Progn 2023;3(1):17–25. DOI: 10.21873/cdp.10174Standing D., Dandawate P., Anant S. Prolactin receptor signaling: a novel target for cancer treatment – exploring anti-PRLR signaling strategies. Front Endocrinol (Lausanne) 2023;13:1112987. DOI: 10.3389/fendo.2022.1112987Standing D., Dandawate P., Anant S. Prolactin receptor signaling: a novel target for cancer treatment – exploring anti-PRLR signaling strategies. Front Endocrinol (Lausanne) 2023;13:1112987. DOI: 10.3389/fendo.2022.1112987Costello L.C. The suppression of prolactin is required for the treatment of advanced prostate cancer. Oncogen (Westerville) 2019;2(3):13. DOI: 10.35702/onc.10013Costello L.C. The suppression of prolactin is required for the treatment of advanced prostate cancer. Oncogen (Westerville) 2019;2(3):13. DOI: 10.35702/onc.10013Porcaro A.B., Tafuri A., Sebben M. et al. Low preoperative prolactin levels predict non-organ confined prostate cancer in clinically localized disease. Urol Int 2019;103(4):391–9. DOI: 10.1159/000496833Porcaro A.B., Tafuri A., Sebben M. et al. Low preoperative prolactin levels predict non-organ confined prostate cancer in clinically localized disease. Urol Int 2019;103(4):391–9. DOI: 10.1159/000496833Costello L.C., Franklin R.B. A proposed efficacious treatment with clioquinol (zinc ionophore) and cabergoline (prolactin dopamine agonist) for the treatment of terminal androgen-independent prostate cancer. Why and how? J Clin Res Oncol 2019;2(1): https://asclepiusopen.com/journal-of-clinical-research-in-оncology/ volume-2-issue-1/1.pdf. PMID: 30828702.Costello L.C., Franklin R.B. A proposed efficacious treatment with clioquinol (zinc ionophore) and cabergoline (prolactin dopamine agonist) for the treatment of terminal androgen-independent prostate cancer. Why and how? J Clin Res Oncol 2019;2(1): https://asclepiusopen.com/journal-of-clinical-research-in-оncology/ volume-2-issue-1/1.pdf. PMID: 30828702.Yang T., Liu Y., Chen S. et al. Serum prolactin level as a predictive factor for abiraterone response in patients with metastatic castration-resistant prostate cancer. Prostate 2022;82(13):1284–92. DOI: 10.1002/pros.24402Yang T., Liu Y., Chen S. et al. Serum prolactin level as a predictive factor for abiraterone response in patients with metastatic castration-resistant prostate cancer. Prostate 2022;82(13):1284–92. DOI: 10.1002/pros.24402Ma J., Mo Y., Tang M. et al. Bispecific antibodies: аrom research to clinical application. Front Immunol 2021;12:626616. DOI: 10.3389/fimmu.2021.626616Ma J., Mo Y., Tang M. et al. Bispecific antibodies: аrom research to clinical application. Front Immunol 2021;12:626616. DOI: 10.3389/fimmu.2021.626616Anderson M.G., Zhang Q., Rodriguez L.E. et al. ABBV-176, a PRLR antibody drug conjugate with a potent DNA damaging PBD cytotoxin and enhanced activity with PARP inhibition. BMC Cancer 2021;21(1):681. DOI: 10.1186/s12885-021-08403-5Anderson M.G., Zhang Q., Rodriguez L.E. et al. ABBV-176, a PRLR antibody drug conjugate with a potent DNA damaging PBD cytotoxin and enhanced activity with PARP inhibition. BMC Cancer 2021;21(1):681. DOI: 10.1186/s12885-021-08403-5Lemech C., Woodward N., Chan N. et al. A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibodydrug conjugate targeting the prolactin receptor, in patients with advanced solid tumors. Invest New Drugs 2020;38(6):1815–25. DOI: 10.1007/s10637-020-00960-zLemech C., Woodward N., Chan N. et al. A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibodydrug conjugate targeting the prolactin receptor, in patients with advanced solid tumors. Invest New Drugs 2020;38(6):1815–25. DOI: 10.1007/s10637-020-00960-z

The authors declare that there are no conflicts of interest present.